Home › NDC Lookup › RxCUI directory › RxCUI 2719198

Deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] — RxCUI 2719198

RxNorm drug concept · Semantic branded drug
RxCUI 2719198 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2719198
Official nameDeflazacort 22.75 MG/ML Oral Suspension [Pyquvi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asPyquvi 22.75 MG/ML Oral Suspension
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Deflazacort: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Deflazacort is used to treat Duchenne muscular dystrophy (DMD), a genetic disease that causes muscles to weaken and break down over time. It's a corticosteroid — a type of anti-inf...
  • Yes — several brands, including Emflaza, Jaythari, and Kymbee tablets, can be crushed and mixed immediately with applesauce if swallowing a whole tablet is difficult. The oral susp...
  • Can my child take the tablet if they have trouble swallowing pills?
  • Many children on deflazacort develop a rounder, puffier face (sometimes called a 'moon face'), gain weight, grow more body hair, and get more frequent infections — these are common...
📖 Read our full Deflazacort guide →

🕸️ Concept Web — How Deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] RxCUI 2719198

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Deflazacort 22396
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pyquvi 2719193
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Deflazacort Oral Suspension 1870963
    • Deflazacort Oral Liquid Product 1870962
    • Deflazacort Oral Product 1157200
    • Deflazacort Oral Suspension [Pyquvi] 2719197
    • Pyquvi Oral Liquid Product 2719196
    • Pyquvi Oral Product 2719195
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Deflazacort 22.75 MG/ML Oral Suspension SCD · 1870964
  • Deflazacort 22.75 MG/ML SCDC · 1870961
  • Deflazacort Oral Suspension SCDF · 1870963
  • Deflazacort Oral Liquid Product SCDG · 1870962
  • Deflazacort Oral Product SCDG · 1157200

Brand-Name Concepts

  • Deflazacort 22.75 MG/ML [Pyquvi] SBDC · 2719194
  • Deflazacort Oral Suspension [Pyquvi] SBDF · 2719197
  • Pyquvi Oral Liquid Product SBDG · 2719196
  • Pyquvi Oral Product SBDG · 2719195
  • Pyquvi BN · 2719193

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2719198 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73289-0089-01 13 mL in 1 BOTTLE (73289-0089-1) PYQUVI Aucta Pharmaceuticals, Inc. 2025-06-30
Observed labelers: Aucta Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.